Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,717
  • Shares Outstanding, K 125,347
  • Annual Sales, $ 7,580 K
  • Annual Income, $ -65,030 K
  • 36-Month Beta 1.26
  • Price/Sales 18.75
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/12/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.05
  • Number of Estimates 4
  • High Estimate -0.05
  • Low Estimate -0.07
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.56 +10.71%
on 02/01/19
2.03 -69.46%
on 01/16/19
-1.37 (-68.84%)
since 01/15/19
3-Month
0.56 +10.71%
on 02/01/19
2.25 -72.44%
on 11/26/18
-1.23 (-66.49%)
since 11/15/18
52-Week
0.56 +10.71%
on 02/01/19
3.59 -82.73%
on 09/26/18
-2.38 (-79.33%)
since 02/15/18

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

AVEO : 0.62 (+2.48%)
CELG : 90.69 (+0.01%)
VRTX : 188.07 (+1.27%)
GILD : 67.59 (+1.84%)
ALKS : 32.54 (+0.12%)
Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).

AVEO : 0.62 (+2.48%)
CELG : 90.69 (+0.01%)
VRTX : 188.07 (+1.27%)
GILD : 67.59 (+1.84%)
REGN : 423.97 (+2.17%)
ALKS : 32.54 (+0.12%)
Bragar Eagel & Squire, P.C. is Investigating AVEO Pharmaceuticals, Inc. (AVEO) on Behalf of Stockholders and Encourages AVEO Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO). Our investigation concerns whether AVEO has violated the federal securities laws and/or...

AVEO : 0.62 (+2.48%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of AVEO Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of AVEO Pharmaceuticals, Inc. ("AVEO" or "the Company") (NASDAQGS: AVEO) concerning possible violations of federal securities laws.

AVEO : 0.62 (+2.48%)
AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA

AVEO Oncology (AVEO) decides against filing NDA for Fotivda on recommendation of the FDA. The agency remains concerned with the overall survival data.

BAYRY : 19.3000 (+3.90%)
AVEO : 0.62 (+2.48%)
GALT : 5.12 (+3.02%)
BMY : 51.67 (+1.65%)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AVEO Pharmaceuticals, Inc. (AVEO)

Attorney Advertising -- (PR NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO)....

AVEO : 0.62 (+2.48%)
AVEO Oncology Announces NDA Timing Update

AVEO Oncology (NASDAQ: AVEO) today announced that it has accepted the recommendation of the U.S. Food and Drug Administration (FDA) not to submit a New Drug Application (NDA) for tivozanib...

AVEO : 0.62 (+2.48%)
Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Realty Income Corporation...

PTCT : 29.68 (+2.17%)
AVEO : 0.62 (+2.48%)
NXTM : 29.30 (+0.45%)
OMI : 7.70 (+1.99%)
UTHR : 119.63 (+0.92%)
O : 70.09 (+0.44%)
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

AVEO : 0.62 (+2.48%)
AVEO Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco...

AVEO : 0.62 (+2.48%)
JPM : 105.55 (+3.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AVEO with:

Business Summary

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is...

See More

Key Turning Points

2nd Resistance Point 0.65
1st Resistance Point 0.64
Last Price 0.62
1st Support Level 0.60
2nd Support Level 0.57

See More

52-Week High 3.59
Fibonacci 61.8% 2.43
Fibonacci 50% 2.08
Fibonacci 38.2% 1.72
Last Price 0.62
52-Week Low 0.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar